Biochips Devices Market Summary
- The global Biochips market is expected to grow at an immense CAGR during forecast period from 2024 to 2030.
- The demand for biochips is primarily being boosted owing to the increasing prevalence of chronic diseases around the globe, growing applications of biochips in various clinical research studies, and the rising demand for point-of-care testing, among others, thereby contributing to the overall growth of the Biochips market.
Key Biochips Market Trends & Insights
- Some of the key market players operating in the Biochips market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Standard BioTools, GE Healthcare, LI-COR, Inc., Qiagen, Randox Laboratories Ltd, Abbott, F. Hoffmann La-Roche, Cepheid Inc., Fluidigm Corporation, BioMerieux SA, and others.
- Among all the regions, North America is estimated to account for the largest share of the Biochips market in the year 2023.
- In the type segment of the biochips market, the lab-on-chips category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with lab-on-chips along with the adoption of personalized medicine and easy accessibility of lab-on-chip technology.
Request for unlocking the CAGR of the "Biochips Market"
Factors Contributing to the Rise in Growth of the Biochips Market
-
Rising Prevalence of Biochips:
The increasing use of biochips across genomics, proteomics, diagnostics, and personalized medicine has significantly contributed to market growth. Their ability to deliver rapid, accurate, and high-throughput analysis makes them indispensable in modern healthcare and life sciences research.
-
Growing Adoption of Biochips:
Biochips are gaining widespread adoption in drug discovery, disease diagnosis, and point-of-care testing due to their efficiency, cost-effectiveness, and reduced sample requirements. Pharmaceutical, biotechnology, and research institutions are increasingly integrating biochips into routine workflows.
-
Biochips Technological Advancements & Product Launches:
Continuous technological innovations, such as lab-on-chip integration, miniaturization, enhanced sensitivity, and automation, along with frequent product launches, are improving performance and expanding application areas, thereby fueling market expansion.
-
Government Awareness Initiatives for Biochips:
Supportive government policies, funding programs, and awareness initiatives promoting advanced diagnostic technologies and precision medicine are accelerating the adoption of biochips in both clinical and research settings.
-
Expanding Access in Emerging Markets:
Improved healthcare infrastructure, rising investments in life sciences, and increasing focus on early disease detection in emerging economies are enhancing access to biochip technologies, creating new growth opportunities for the global biochips market.
What are the latest Biochips Market Dynamics and Trends?
In the global biochips market, the estimated high numbers of chronic and infectious diseases are expected to drive the demand for biochips in the upcoming years. Globally, chronic diseases (CDs) have been observed to be the leading causes of disability and morbidity and since these diseases are chronic, skilled healthcare expertise along with the latest treatment technologies are required to timely treat the chronic disease.
For example, an article published by the European Public Health Conference in January 2022, reported that more than 3 million people will be affected by cancer by 2030 in Europe. In addition, according to a research paper published by the Journal Plos One in March 2022, it stated that 21% of the elderly population in India had at least one chronic disease, being the leading cause of death and mortality among the geriatric population in India.
In this direction, research toward developing new lab-on-a-chip-based POC systems for the diagnosis of chronic diseases is an emerging area. Thus, a high incidence of chronic diseases is expected to drive the growth of the studied market.
Moreover, the application of biochips in biomedical and biotechnological research is growing, especially in the fields of proteomics and genomics. Proteomics is being used extensively in drug and biomarker discovery. For instance, a particular advantage of protein biochips is their tendency towards miniaturization, resulting in a low sample consumption..
Moreover, recent product development activities in the biochips market are also expected to spur the demand for biochips in the upcoming years.
For instance, In July 2023, Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, filed a patent for a revolutionary multiplex biochip Opteev multiplex biochip for respiratory infection diagnostics. The groundbreaking polymer-based biochip offered the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.
Hence, the interplay of all the above-mentioned factors is anticipated to increase the overall market growth for Biochips during the forecast period from 2023 – 2030.
However, the availability of alternative technologies, and constraints associated with lab-on-chip devices, among others may restrict the growth of the overall market for Biochips during the forecast period.
Biochips Market Report Segmentation
Biochips Market By Type (DNA Chips, Protein Chips, Lab-On-Chips, And Others), Application (Genomics And Proteomics, Drug Discovery, Diagnostics, IVD & POC, Gene Expression, And Others), End-User (Hospitals And Diagnostic Centers, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, And Others), And Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the type segment of the biochips market, the lab-on-chips category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with lab-on-chips along with the adoption of personalized medicine and easy accessibility of lab-on-chip technology.
Lab-on-a-chips are biochips that are microfluidic devices conducting several laboratory functions and fluid analyses at rapid speeds designed with micro-channels smaller than a single cell, with a large surface-area-to-volume ratio where liquids follow a laminar flow pathway. Lab on a chip shows the ability to control cells at the single-cell level in seconds. It also includes applications such as micro patch clamp, control of stem cell differentiation, high-speed flow cytometry, and cell sorting. In addition, recently extensive research has been focused on using lab-on-a-chip microfluidics and highly parallelized microchemical reactors.
For example, the lab-on-chip microfluidic is emerging as a molecular biological tool for DNA/RNA amplification and detection like ELVESYS developed the world's fastest qPCR system - Fastgene. Moreover, in February 2022, Onera Health launched the Onera Biomedical-Lab-on-Chip, an ultra-low-power bio-signal sensor subsystem for wearable devices; designed to process multiple bio-signals.
Thus, due to the increasing number of clinical research, developmental activities, rising technological advancements, and adoption of personalized medicine, among others, the lab-on-a-chip biochips segment is expected to grow substantially, thus supporting the overall market growth for Biochips during the forecast period from 2024 to 2030.
Biochips Market Segmentation
Biochips Market By Type
- DNA Chips
- Protein Chips
- Lab-on-Chips
- Others
Biochips Market By Application
- Genomics and Proteomics
- Drug Discovery
- Diagnostics
- IVD & Point-of-Care (POC)
- Gene Expression
- Others
Biochips Market By End User
- Hospitals and Diagnostic Centers
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Others.
Biochips Market by Geography
-
North America Biochips Market
- United States Biochips Market
- Canada Biochips Market
- Mexico Biochips Market
-
Europe Biochips Market
- France Biochips Market
- Germany Biochips Market
- United Kingdom Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- Russia Biochips Market
- Rest of Europe
-
Asia-Pacific Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Rest of Asia-Pacific
-
Rest of the World (RoW)
- Middle East Biochips Market
- Africa Biochips Market
- South America Biochips Market
Biochips Devices Regional Insights
North America is expected to witness the fastest growth in the overall Biochips Market
Among all the regions, North America is estimated to account for the largest share of the Biochips market in the year 2023. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, diagnostic procedures, research activities, and government funding for the masses in North America, among others during the forecast period from 2024-2030.Major collaborations among key players in the region are expected to drive the the demand for biochips in the upcoming years. For instance, in September 2022, the US-headquartered activities with healthcare giants that are extensively investing in R&D in microarray technology. For instance, in September 2022, Illumina Inc. launched the NovaSeq X Series, enabling faster and more powerful sustainable sequencing. The revolutionary new technology, NovaSeq X Plus could generate 20,000+ whole genomes per year, therefore accelerating genomic discovery and clinical insights to transform patient lives. Thus, such collaborative developments in the region are driving the growth of the biochips market in the region.
Moreover, the increasing incidence of chronic and lifestyle diseases in the region is also contributing to the growth of the biochips market in the North America region. For instance, as per the Canadian Cancer Statistics (2021), an estimated 229,200 Canadians were diagnosed with cancer in 2021. Similarly, according to the International Diabetes Federation (IDF), in 2023, an estimated 14 million adults in Mexico were living with diabetes. Thus, such a high number of people living with chronic and lifestyle diseases in North America is also contributing to the growth of the biochips market, by increasing the rates of their diagnosis, and treatment and opening up opportunities for their clinical research in the upcoming years.
Thus, due to the presence of key market players, the increase in chronic diseases, the development of healthcare infrastructure, and recent research activities, among others in North America is expected to witness significant growth in the biochips market over the forecast period.
Therefore, the interplay of all the above-mentioned factors is expected to aid in the growing demand for Biochips, thus driving the overall regional market for the North America Biochips.
Who are the major players in the Biochips Market?
Some of the key market players operating in the Biochips market include :
- Thermo Fisher Scientific, Inc.,
- Agilent Technologies, Inc.,
- PerkinElmer Inc., Illumina, Inc.,
- Bio-Rad Laboratories, Inc.,
- Standard BioTools,
- GE Healthcare,
- LI-COR, Inc.,
- Qiagen,
- Randox Laboratories Ltd,
- Abbott,
- F. Hoffmann La-Roche,
- Cepheid Inc.,
- Fluidigm Corporation,
- BioMerieux SA, and others.
Recent Developmental Activities in the Biochips Market:
- In June 2023, ACROBiosystems, under its Aneuro brand, announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization.
- In January 2022, researchers from the Universidad Carlos III de Madrid (UC3M), the Universidad Politécnica de Madrid (UPM), and other organizations innovated a new biochip device made of biocompatible and micro-machined adhesive vinyl sheets, that simplified the process of manufacturing in vitro skin in the laboratory and other complex multi-layer tissues. Human skin modeled using this device could be used in medicine and cosmetic testing, which would reduce the cost of preclinical trials.
- In April 2019, Qurin Diagnostics B.V. and Lionix International B.V. acquired Surfix B.V., which is a supplier of custom-made nanocoatings, complementary to the products and services offered by Qurin and LioniX International. The companies planned on working together closely on early cancer detection using a sensitive biochip, bringing together their respective complementary technologies.
Biochips Market Recent Industry Trends and Milestones (2022-2025) | |
|---|---|
| Category | Key Developments (2022–2025) |
| Biochips Market Product Launches |
Thermo Fisher Scientific launched a new lab-on-a-chip diagnostic platform (PhenoChip) for high-throughput oncology and infectious disease testing in 2025.Bio-Rad Laboratories introduced a new lab-on-a-chip rapid immunoassay platform in 2025.Randox Laboratories launched a biochip-based genetic test for type 1 diabetes (2024).Boston Micro Fabrication launched a division for 3D-printed organ-on-a-chip platforms (2024). |
| Biochips Market Regulatory Approvals |
Regulatory pathways expanded for biochip diagnostics with increased FDA clearances; industry reports indicate ~23% more biochip-based diagnostic devices approved in Q4 2024 vs 2023. |
| Biochips Market Partnerships |
Roche & Illumina announced a strategic collaboration (March 2025) to co-develop integrated microarray diagnostics. Illumina partnered with Merck Group (August 2024) to co-develop lab-on-a-chip genomic profiling assays. Abbott Laboratories and Siemens Healthineers partnered (July 2025) on microfluidic BioMEMS diagnostic chips. |
| Biochips Market Acquisitions |
Thermo Fisher Scientific acquired a MEMS/microfluidics startup in 2025 to expand point-of-care biochip diagnostics capabilities. |
| Biochips Market Company Strategy |
Major players (Abbott, Thermo Fisher, Agilent, Illumina) are increasing investments in microarray, lab-on-a-chip, and BioMEMS technologies to capture growth in diagnostics and research markets.Strategic focus expanded on personalized medicine, point-of-care diagnostics, and AI integration in biochip platforms. |
| Biochips Market Setbacks |
Regulatory challenges remain a restraint, as approval processes are lengthy and non-uniform across regions, slowing market entry. High development and manufacturing complexity limits adoption in cost-sensitive healthcare systems. |
| Biochips Market Emerging Technology |
Organ-on-a-chip and wearable/implantable LoC biosensors are gaining traction as next-generation platforms with real-time monitoring capabilities.Integration of AI and microfluidics for portable, high-throughput diagnostics continues to advance. |
Impact Analysis
AI Advancements in Biochips
- Enhanced Data Analysis and Interpretation: AI-powered algorithms enable rapid processing and analysis of complex biological data generated by biochips, improving accuracy in genomics, proteomics, and biomarker identification.
- Improved Diagnostic Precision: The integration of AI with biochips enhances pattern recognition and predictive analytics, leading to earlier and more accurate disease detection, particularly in oncology, infectious diseases, and genetic disorders.
- Acceleration of Drug Discovery: AI-driven biochip platforms support high-throughput screening and target validation, significantly reducing time and cost in drug discovery and development processes.
- Automation and Workflow Optimization: AI enables automation of biochip-based experiments, minimizing human intervention, reducing errors, and increasing reproducibility in clinical and research laboratories.
- Personalized and Precision Medicine: By combining AI analytics with biochip data, healthcare providers can better tailor treatments based on individual genetic and molecular profiles, supporting personalized medicine approaches.
- Real-Time Monitoring and Decision Support: AI-integrated biochips facilitate real-time data monitoring and clinical decision support, improving patient outcomes and enabling more proactive healthcare management.
- Continuous Learning and Performance Improvement: Machine learning models continuously learn from new biochip data, enhancing system performance, adaptability, and predictive accuracy over time.
Tariff Inclusion in Biochips: How This Analysis Helps Clients
-
Cost Management: Tariff inclusion analysis helps clients understand the impact of import and export duties on biochip components and finished products, enabling accurate cost forecasting, pricing strategies, and margin protection.
-
Supply Chain Optimization: By evaluating tariffs across regions, companies can identify cost-efficient sourcing locations, optimize manufacturing footprints, and reduce dependency on high-tariff trade routes, improving overall supply chain resilience.
-
Regulatory Navigation: Tariff analysis provides clarity on country-specific trade regulations, customs duties, and compliance requirements, helping clients navigate complex regulatory environments and avoid unexpected financial or operational disruptions.
-
Strategic Planning: Insights into tariff structures support long-term strategic decisions such as market entry, regional expansion, partnership selection, and localization strategies, allowing companies to align business plans with evolving trade policies in the biochips market.
| Company Name | Total Funding | Main Products / Focus | Stages of Development | Core Technology |
|---|---|---|---|---|
| Nomic Bio | > $60 M (Series B $42 M) | Protein profiling & multiplex biochip platform | Scale-up & commercial expansion | High-throughput proteomics biochips (nELISA) |
| CN Bio | ~$21 M (Series B) | Organ-on-Chip systems for drug discovery & toxicology | Growth/Series B | Microphysiological Organ-on-Chip platforms |
| Encapsulate, Inc. | ~$1.8 M seed + ~$4.9 M grants | Personalized cancer therapy biochips & automated selection | Early stage / seed | Automated biochip systems for therapy selection |
| Mimetas | > $25 M in Series A/B funding | 3D organ-ready biochips for tissue modeling | Expansion phase | Organ-on-a-chip microfluidic platforms |
| Sphere Bio (formerly Sphere Fluidics) | ~£47 M total funding historically | Single-cell analysis & microfluidic biochips | R&D / acquisition into Fluidic Sciences | Cyto-Mine microfluidic system & biochip platforms |
Key Takeaways from the Biochips Market Report Study:
- Market size analysis for current Biochips market size (2023), and market forecast for 5 years (2024-2030)
- Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the global Biochips market.
- Various opportunities available for other competitors in the Biochips market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current Biochips market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for Biochips market growth in the coming future?
Target Audience Who Can Benefit from This Biochips Market Report Study
- Biochips product providers
- Research organizations and consulting companies
- Biochips-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in Biochips
- Various end-users who want to know more about chronic disorders and their related technology equipment market, along with the latest technological developments in the Biochips market.
Frequently Asked Questions for the Biochips Market
1. What are biochips?
Biochips, also known as microchips or DNA microarrays, are similar to computerized devices that can host a large number of simultaneous biochemical reactions and thus are used as a carrier for biological samples.
2. What is the market for global Biochips?
The global Biochips market was valued at USD XX million in 2022, growing at a CAGR of XX% during the forecast period from 2024 to 2030 to reach USD XX million by 2030.
3. What are the drivers for the global Biochips market?
The demand for biochips is primarily being boosted owing to the increasing prevalence of chronic diseases around the globe, growing applications of biochips in various clinical research studies, and the rising demand for point-of-care testing, among others, thereby contributing to the overall growth of the Biochips market during the forecast period from 2024-2030.
4. Who are the key players operating in the global Biochips market?
Some of the key market players operating in the Biochips market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Standard BioTools, GE Healthcare, LI-COR, Inc., Qiagen, Randox Laboratories Ltd, Abbott, F. Hoffmann La-Roche, Cepheid Inc., Fluidigm Corporation, BioMerieux SA, and others.
5. Which region has the highest share in the Biochips market?
North America is expected to dominate the overall Biochips market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, diagnostic procedures, research activities, and government funding for the masses in North America, among others during the forecast period from 2024-2030.
